Advanced Solid Tumor Clinical Trials in Louisville, Kentucky

4 studies are recruiting for advanced solid tumor in Louisville, Kentucky right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

    This is a first-in-human (FIH), open-label, multi-site study which will evaluate the safety, efficacy, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 in participants with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Norton Cancer Institute PARENT, Louisville, Kentucky
    Locations
    11 in total
    Run by
    BioNTech SE

    See if you can join NCT06750185 on ClinicalTrials.gov

  2. Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

    BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Norton Cancer Center, Louisville, Kentucky
    Locations
    21 in total
    Run by
    OncoC4, Inc.

    See if you can join NCT06635785 on ClinicalTrials.gov

  3. Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

    This is a Phase I/II open label study of intravenous (IV) infusion of ONC-841 as a single agent or in combination in patients with advanced/metastatic solid tumors. The study will evaluate seven dose levels of ONC-841. The Phase 1 part is dose escalation with 7 dose levels of ONC-841 and the dose e…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Norton Cancer Center, Louisville, Kentucky
    Locations
    8 in total
    Run by
    OncoC4, Inc.

    See if you can join NCT06352359 on ClinicalTrials.gov

  4. A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

    This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous (IV) infusion to subjects with advanced solid tumors, including diffuse large B-cell lymphoma (DLBC…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Norton Cancer Institute, Louisville, Kentucky
    Locations
    5 in total
    Run by
    Ranok Therapeutics (Hangzhou) Co., Ltd.

    See if you can join NCT05487170 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.